Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.63 |
| ▸ | PPARD | Q03181 | 2/20 | 0.63 |
| ▸ | PPARA | Q07869 | 2/20 | 0.63 |
| ▸ | ESR1 | P03372 | 4/20 | 0.57 |
| ▸ | TTR | P02766 | 3/20 | 0.57 |
| ▸ | AHR | P35869 | 3/20 | 0.57 |
| ▸ | NQO2 | P16083 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | BCR | P11274 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.57 |
| ▸ | TUBB | P07437 | 2/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797096 | 1.00 | FFAR1 (0.63) | FFAR1PPARGPPARDPPARAESR1 | |
| SCHEMBL28469011 | 0.94 | ESR1 (0.64) | FFAR1PPARGPPARDPPARAESR1 | |
| SCHEMBL28467186 | 0.88 | KMT2A (0.73) | FFAR1PPARGPPARDPPARATTR | |
| SCHEMBL28462780 | 0.88 | KMT2A (0.73) | FFAR1PPARGPPARDPPARATTR | |
| SCHEMBL28467188 | 0.88 | KMT2A (0.73) | FFAR1PPARGPPARDPPARATTR | |
| SCHEMBL18380781 | 0.84 | ALB (0.62) | FFAR1PPARGPPARDPPARAESR1 | |
| SCHEMBL28462762 | 0.84 | ALB (0.62) | FFAR1PPARGPPARDPPARAESR1 | |
| SCHEMBL19039763 | 0.83 | KMT2A (0.56) | FFAR1PPARGPPARDPPARAESR1 | |
| SCHEMBL19690708 | 0.82 | HTT (0.66) | FFAR1CYP1A2NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL3362815 | 0.82 | ESR1 (0.58) | FFAR1PPARGPPARDPPARAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111777577-A | Taxol derivative and application thereof in preparation of medicine for preventing and treating human malignant tumor | 天津仁雨生物科技有限公司 | 2020-10-16 | — | — | CN | claimed |
| CN-111777577-A | Taxol derivative and application thereof in preparation of medicine for preventing and treating human malignant tumor | 天津仁雨生物科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-07-06 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160326200-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | UNIV GEORGIA (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3080137-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | The University Of Georgia Research Foundation, Inc (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089389-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | FFAR1 1416/4885PPARG 1066/4885PPARD 2299/4885 |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | FFAR1 4650/4885PPARG 832/4885PPARD 1011/4885 |
| US-20160326200-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | FFAR1 1416/4885PPARG 1066/4885PPARD 2299/4885 |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | FFAR1 2756/4885PPARG 1310/4885PPARD 1989/4885 |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | FFAR1 4650/4885PPARG 832/4885PPARD 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.